X-Zell Inc. news

X-ZELL is proud to announce the appointment of Michael Tillmann as member of the company’s executive board.

Drawing on more than 30 years of experience in the pharmaceutical and diagnostics industry, Mr Tillmann previously held the CEO position at Roche Diagnostics North America and Asia Pacific. Between 2006 and 2010, he also served as a member of t

Singaporean medical technology specialist X-ZELL has appointed Sebastian Grote as Managing Director, effective from 1 March 2022.

Grote previously served as Head of Marketing & Strategy at X-ZELL and has been with the company since 2017, when it first came out of stealth mode to raise a two-part, USD 5.6m seed round.

Since then, he initiated a series of

New study data presented at the European Congress of Cytology – held from 3-6 Oct in Warsaw, Poland – confirmed that X-ZELL is able to detect tumour-associated circulating atypical cells in the blood of lung cancer patients 

The dataset comprised interim results from a pilot study carried out in Thailand by X-ZELL and Dr Kittipong Maneechotesuwan from Mahidol University’s Siriraj Hospital in Bangkok, and was presented by X-ZELL Founder & CEO, Dr

Award-winning Singaporean start-up, X-ZELL, has announced the formation of a new, interdisciplinary Imaging Technology division.

The announcement comes on the back of a new collaboration agreement with Finnish Artificial Intelligence (AI) specialist, Aiforia Technologies, and is part of the ongoing digitisation of X-ZELL’s patented rare cell detection technology.

X-ZELL&rs

X-ZELL’s widely recognised high-gradient magnetic Cell Separator (hMX™) is now available to researchers worldwide.

Previously exclusive to X-ZELL, the patented system is part of the company’s single-cell diagnostics platform, which is capable of isolating and visualising individual atypical cells from a small 10mL blood sample.

According to X-ZELL’s Head of Engineering & Product Development, Sven Strache, the technology is crucial to the routin